US equities
|
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
ImmunityBio, Inc. - Common Stock
(NQ:
IBRX
)
6.020
-0.550 (-8.37%)
Official Closing Price
Updated: 4:15 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ImmunityBio, Inc. - Common Stock
< Previous
1
2
...
18
19
20
21
22
23
24
25
Next >
ImmunityBio to Present at the Jefferies 2021 Virtual Healthcare Conference
May 24, 2021
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types Who Failed Prior Checkpoint Therapy at ASCO 2021
May 20, 2021
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Shares Jump As It Plans To Start Testing Memory Cytokine-Enriched NK Cell Platform In Solid Tumors Patients
↗
May 17, 2021
ImmunityBio Inc (NASDAQ: IBRX) has received FDA authorization to conduct a Phase 1 study to evaluate the m-ceNK platform combined with Anktiva (N-803) in...
Via
Benzinga
FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors
May 17, 2021
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients
May 04, 2021
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva With Antiretroviral Therapy to Inhibit HIV Reservoirs
April 29, 2021
From
ImmunityBio, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
April 27, 2021
Gainers BioVie (NASDAQ:BIVI) shares rose 11.62% to $24.0 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 27.3K shares,...
Via
Benzinga
ImmunityBio Announces 100th Patient Dosed with Proprietary Natural Killer Cells; NK Trials Cover Multiple Indications
April 22, 2021
From
ImmunityBio, Inc.
Via
Business Wire
Single Dose Of ImmunityBio's Dual Antigen COVID-19 Vaccine Induces Ten-Fold Increase In T-Cell Responses
↗
April 08, 2021
ImmunityBio Inc (NASDAQ: IBRX) has reported initial data from the Phase 1 study evaluating its hAd5 COVID-19 vaccine candidate in healthy participants. Just...
Via
Benzinga
ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2
April 08, 2021
From
ImmunityBio, Inc.
Via
Business Wire
51 Biggest Movers From Yesterday
↗
April 07, 2021
Gainers UTime Limited (NASDAQ: UTME) shares jumped 875% to close at $39.00 on Tuesday after the company priced its IPO at $4 per share. Romeo Power, Inc. (NYSE: RMO) climbed 59.6...
Via
Benzinga
Topics
Initial Public Offering
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
April 06, 2021
Gainers Second Sight Medical (NASDAQ:EYES) stock increased by 33.37% to $9.87 during Tuesday's regular session. As of 12:32 EST, this security is trading at a volume...
Via
Benzinga
< Previous
1
2
...
18
19
20
21
22
23
24
25
Next >